According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Boehringer Ingelheim Limited. Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and ...

Boehringer Ingelheim, GoodRx team to boost access to Humira biosimilars By Paige Minemyer Jul 18, 2024 3:00pm GoodRx Boehringer Ingelheim Drug Prices biosimilars ...

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...

Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a month for its entire line of inhalers that are used to combat asthma and chronic obstructive ...

Boehringer Ingelheim's U.S. headquarters in Ridgefield, Conn. BI announced in winter 2018 it has increased its investment into a fund that promotes innovation by start-up companies.